Multicenter Trial of Immunotherapy With House Dust Mite Allergoid

PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

December 31, 2011

Conditions
Rhinoconjunctivitis
Interventions
BIOLOGICAL

specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)

"Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued"

Trial Locations (1)

21465

Allergopharma GmbH & Co. KG, Reinbek

All Listed Sponsors
lead

Allergopharma GmbH & Co. KG

INDUSTRY

NCT00540631 - Multicenter Trial of Immunotherapy With House Dust Mite Allergoid | Biotech Hunter | Biotech Hunter